Elanco Animal Health Inc. has announced that Zenrelia™ (ilunocitinib) has received approval from the European Commission, marking a significant advancement in the EU's canine dermatology market. This approval confirms Zenrelia's effectiveness and safety as a once-daily oral JAK inhibitor for managing pruritus and atopic dermatitis in dogs aged 12 months and older. The approval is a key milestone for Elanco, enhancing their position as leaders in pet health innovation. Zenrelia is already available in Brazil, Canada, Japan, and the United States, with further global approvals anticipated. The product launch in the EU will commence immediately, with availability expected by the end of Q3 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.